A case of autoimmune pulmonary alveolar proteinosis with severe respiratory failure treated with segmental lung lavage and oral statin therapy.
Respir Med Case Rep
; 38: 101684, 2022.
Article
en En
| MEDLINE
| ID: mdl-35707405
Pulmonary alveolar proteinosis (PAP) is a diffuse lung disease characterized by the accumulation of alveolar surfactants due to dysfunction of granulocyte-macrophage colony-stimulating factor-dependent cholesterol clearance. Whole-lung lavage is the current standard of care for PAP, but it can lead to the exacerbation of hypoxia. A medication targeting cholesterol homeostasis is a promising therapy for refractory PAP. We present a case of autoimmune PAP with severe hypoxia that was successfully treated with segmental lung lavage (SLL). Following SLL for disease relapse, statin treatment for dyslipidemia was started. After initiating statin treatment, the patient did not require bronchoalveolar lavage for 10 months.
BAL, bronchoalveolar lavage; CT, computed tomography; Dyslipidemia; ECMO, extracorporeal membrane oxygenation; GM-CSF, granulocyte-macrophage colony-stimulating factor; Granulocyte-macrophage colony-stimulating factor; HOT, home oxygen therapy; Non-invasive cholesterol treatment; PAP, pulmonary alveolar proteinosis; Pulmonary alveolar proteinosis; SLL, segmental lung lavage; Segmental lung lavage; WLL, whole-lung lavage; Whole lung lavage
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Respir Med Case Rep
Año:
2022
Tipo del documento:
Article
País de afiliación:
Japón